Copper-Free Crosslinked Alginic Acid via Huisgen Reaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a demand for novel alginic acid derivatives and methods to manufacture novel crosslinked alginic acid that offer improved stability and permeability for biomedical applications, as existing methods face challenges in achieving these properties without copper catalysts and high-temperature conditions.
Innovation Solution
The development of alginic acid derivatives with introduced reactive groups, such as cyclic alkyne and azide groups, that undergo a Huisgen reaction to form crosslinked structures without a copper catalyst, allowing for chemical and ionic crosslinking, resulting in a stable and permeable gel suitable for biomedical uses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If copper catalysts and high-temperature conditions are used for crosslinking, then crosslinking efficiency is improved, but biocompatibility and safety deteriorate due to copper toxicity
Solution Approach 1:
The patent removes the copper catalyst from the crosslinking system entirely, replacing it with a copper-free Huisgen reaction that proceeds under physiological conditions. This extraction of the harmful copper catalyst resolves the contradiction by eliminating copper toxicity while maintaining crosslinking functionality through alternative reaction mechanisms.
Solution Approach 2:
The patent changes the reaction parameters from high-temperature copper-catalyzed conditions to room temperature copper-free conditions. By modifying the temperature parameter to physiological range and eliminating the copper catalyst, the system achieves biocompatible crosslinking that maintains efficiency without toxicity.
2Speed
If conventional crosslinking methods are used, then crosslinking speed is improved, but gel stability and controlled permeability deteriorate
Solution Approach 1:
The patent creates a composite crosslinked structure combining covalent crosslinks (from Huisgen reaction) and ionic crosslinks (from calcium ions). This composite approach provides both rapid crosslinking speed from the chemical reaction and enhanced gel stability with controlled permeability from the dual-crosslinking mechanism.
Solution Approach 2:
The patent introduces reactive groups (cyclic alkyne and azide) into the alginic acid derivatives beforehand, enabling rapid crosslinking when mixed. This preliminary functionalization allows fast crosslinking speed upon contact while the pre-designed crosslinking architecture ensures gel stability and controlled permeability.
3Adaptability or versatility
If reactive groups are introduced into alginic acid, then crosslinking capability is improved, but manufacturing complexity worsens
Solution Approach 1:
The patent uses water-soluble protecting groups as intermediaries during manufacturing. These protecting groups enable controlled introduction of reactive groups, simplify purification by maintaining water solubility, and can be removed under mild conditions. This intermediary approach enhances crosslinking capability while managing manufacturing complexity through facilitated synthesis and purification steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crosslinked alginic acid derivatives provide enhanced stability and controlled permeability, ensuring biocompatibility and safety for biomedical applications without the risks associated with copper toxicity, while maintaining effective crosslinking at room temperature.
Implementation Method 1
alginic acid derivatives with introduced reactive groups, such as cyclic alkyne and azide groups, that undergo a Huisgen reaction to form crosslinked structures
Implementation Method 2
allowing for chemical and ionic crosslinking, resulting in a stable and permeable gel
Data Source
AI summary
The present invention provides alginic acid derivatives represented by formula (1) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (1) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.